Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

被引:14
作者
Burdge, Gemma [1 ]
Hardman, Alice [1 ]
Carbery, Isabel [1 ]
Broglio, Giacomo [1 ,2 ]
Greer, Dan [1 ]
Selinger, Christian P. [1 ,3 ]
机构
[1] Leeds Teaching Hosp NHS Trust, Gastroenterol, Leeds LS7 4SA, W Yorkshire, England
[2] IRCCS Fdn Policlin San Matteo, Internal Med, I-27100 Pavia, Italy
[3] Univ Leeds, Res Inst, St James Hosp, Leeds LS9 7TF, W Yorkshire, England
关键词
inflammatory bowel disease; infliximab; vedolizumab; INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE THERAPY; CROHNS-DISEASE; INDUCTION;
D O I
10.3390/jcm11195669
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors.
引用
收藏
页数:7
相关论文
共 14 条
[1]   How do patients with inflammatory bowel disease want their biological therapy administered? [J].
Allen, Patrick B. ;
Lindsay, Hannah ;
Tham, Tony C. K. .
BMC GASTROENTEROLOGY, 2010, 10
[2]   When to use biological agents in inflammatory bowel disease [J].
Corte, Crispin ;
Saxena, Payal ;
Tattersall, Stephen ;
Selinger, Christian ;
Leong, Rupert W. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (07) :1141-1149
[3]   Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration [J].
Denesh, Deepa ;
Carbonell, Jenelyn ;
Kane, John S. ;
Gracie, David ;
Selinger, Christian P. .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (09) :1091-1096
[4]   Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis [J].
Feagan, Brian G. ;
Rutgeerts, Paul ;
Sands, Bruce E. ;
Hanauer, Stephen ;
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Van Assche, Gert ;
Axler, Jeffrey ;
Kim, Hyo-Jong ;
Danese, Silvio ;
Fox, Irving ;
Milch, Catherine ;
Sankoh, Serap ;
Wyant, Tim ;
Xu, Jing ;
Parikh, Asit .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :699-710
[5]   Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].
Hanauer, SB ;
Feagan, BG ;
Lichtenstein, GR ;
Mayer, LF ;
Schreiber, S ;
Colombel, JF ;
Rachmilewitz, D ;
Wolf, DC ;
Olson, A ;
Bao, WH ;
Rutgeerts, P .
LANCET, 2002, 359 (9317) :1541-1549
[6]   Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD [J].
Kennedy, Nicholas A. ;
Lin, Simeng ;
Goodhand, James R. ;
Chanchlani, Neil ;
Hamilton, Benjamin ;
Bewshea, Claire ;
Nice, Rachel ;
Chee, Desmond ;
Cummings, J. R. Fraser ;
Fraser, Aileen ;
Irving, Peter M. ;
Kamperidis, Nikolaos ;
Kok, Klaartje B. ;
Lamb, Christopher Andrew ;
Macdonald, Jonathan ;
Mehta, Shameer ;
Pollok, Richard C. G. ;
Raine, Tim ;
Smith, Philip J. ;
Verma, Ajay Mark ;
Jochum, Simon ;
McDonald, Timothy J. ;
Sebastian, Shaji ;
Lees, Charlie W. ;
Powell, Nick ;
Ahmad, Tariq .
GUT, 2021, 70 (10) :1884-1893
[7]   Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic [J].
Kennedy, Nicholas A. ;
Hansen, Richard ;
Younge, Lisa ;
Mawdsley, Joel ;
Beattie, R. Mark ;
Din, Shahida ;
Lamb, Christopher A. ;
Smith, Philip J. ;
Selinger, Christian ;
Limdi, Jimmy ;
Iqbal, Tariq H. ;
Lobo, Alan ;
Cooney, Rachel ;
Brain, Oliver ;
Gaya, Daniel R. ;
Murray, Charles ;
Pollok, Richard ;
Kent, Alexandra ;
Raine, Tim ;
Bhala, Neeraj ;
Lindsay, James O. ;
Irving, Peter M. ;
Lees, Charlie W. ;
Sebastian, Shaji .
FRONTLINE GASTROENTEROLOGY, 2020, 11 (05) :343-350
[8]   British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [J].
Lamb, Christopher Andrew ;
Kennedy, Nicholas A. ;
Raine, Tim ;
Hendy, Philip Anthony ;
Smith, Philip J. ;
Limdi, Jimmy K. ;
Hayee, Bu'Hussain ;
Lomer, Miranda C. E. ;
Parkes, Gareth C. ;
Selinger, Christian ;
Barrett, Kevin J. ;
Davies, R. Justin ;
Bennett, Cathy ;
Gittens, Stuart ;
Dunlop, Malcolm G. ;
Faiz, Omar ;
Fraser, Aileen ;
Garrick, Vikki ;
Johnston, Paul D. ;
Parkes, Miles ;
Sanderson, Jeremy ;
Terry, Helen ;
Gaya, Daniel R. ;
Iqbal, Tariq H. ;
Taylor, Stuart A. ;
Smith, Melissa ;
Brookes, Matthew ;
Hansen, Richard ;
Hawthorne, A. Barney .
GUT, 2019, 68 :S1-S106
[9]   Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies [J].
Reinisch, Walter ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Feagan, Brian G. ;
Rachmilewitz, Daniel ;
Hanauer, Stephen B. ;
Lichtenstein, Gary R. ;
de Villiers, Willem J. S. ;
Blank, Marion ;
Lang, Yinghua ;
Johanns, Jewel ;
Colombel, Jean Frederic ;
Present, Daniel ;
Sands, Bruce E. .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (02) :201-211
[10]   Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis [J].
Sandborn, William J. ;
Baert, Filip ;
Danese, Silvio ;
Krznaric, Zeljko ;
Kobayashi, Taku ;
Yao, Xiaopan ;
Chen, Jingjing ;
Rosario, Maria ;
Bhatia, Siddharth ;
Kisfalvi, Krisztina ;
D'Haens, Geert ;
Vermeire, Severine .
GASTROENTEROLOGY, 2020, 158 (03) :562-+